Amgen Inc. (NASDAQ:AMGN) Receives $351.65 Consensus Target Price from Brokerages

Amgen Inc. (NASDAQ:AMGN) has been given an average recommendation of “Moderate Buy” by the twenty-seven ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $354.0435.

AMGN has been the topic of a number of recent analyst reports. Leerink Partners raised their price target on Amgen from $305.00 to $355.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th. Piper Sandler raised their target price on shares of Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a report on Friday, November 14th. Oppenheimer set a $400.00 price target on shares of Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. UBS Group increased their price target on shares of Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Finally, Royal Bank Of Canada boosted their price objective on shares of Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares in the company, valued at $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.69% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Amgen

Several hedge funds and other institutional investors have recently made changes to their positions in AMGN. Faithward Advisors LLC acquired a new position in Amgen during the 4th quarter worth approximately $449,000. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Amgen during the fourth quarter worth $44,000. LFG Wealth Partners LLC acquired a new position in shares of Amgen during the fourth quarter worth $266,000. OMERS ADMINISTRATION Corp lifted its stake in shares of Amgen by 60.3% in the 4th quarter. OMERS ADMINISTRATION Corp now owns 33,633 shares of the medical research company’s stock valued at $11,008,000 after acquiring an additional 12,656 shares during the last quarter. Finally, Tobias Financial Advisors Inc. bought a new position in shares of Amgen in the 4th quarter valued at $213,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Performance

NASDAQ AMGN opened at $369.19 on Tuesday. The firm has a 50-day moving average price of $338.43 and a two-hundred day moving average price of $314.29. Amgen has a 12-month low of $261.43 and a 12-month high of $385.12. The company has a market capitalization of $198.80 billion, a P/E ratio of 25.94, a P/E/G ratio of 3.78 and a beta of 0.46. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts anticipate that Amgen will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. Amgen’s payout ratio is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.